Edition:
United States

Apricus Biosciences Inc (APRI.OQ)

APRI.OQ on NASDAQ Stock Exchange Capital Market

1.49USD
18 Aug 2017
Change (% chg)

$-0.01 (-0.67%)
Prev Close
$1.50
Open
$1.52
Day's High
$1.53
Day's Low
$1.42
Volume
49,864
Avg. Vol
76,093
52-wk High
$4.94
52-wk Low
$0.87

APRI.OQ

Chart for APRI.OQ

About

Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company's drug delivery technology is a permeation enhancer called NexACT. The... (more)

Overall

Beta: 0.53
Market Cap(Mil.): $19.05
Shares Outstanding(Mil.): 12.78
Dividend: --
Yield (%): --

Financials

  APRI.OQ Industry Sector
P/E (TTM): -- 31.45 32.56
EPS (TTM): -0.83 -- --
ROI: -- 15.33 14.89
ROE: -- 16.35 16.13

BRIEF-Apricus Biosciences Q2 loss per share $0.13

* Apricus Biosciences provides corporate update and second quarter 2017 financial results

Aug 02 2017

BRIEF-Apricus Biosciences reports initiation of vitaros drug-device human factors study

* Apricus Biosciences announces the initiation of vitaros drug-device human factors study

May 04 2017

CORRECTED-BRIEF-Apricus Biosciences sees offering of up to 5 mln units (April 20)

* Now sees offering of up to 5 million units consisting of one share of common stock and warrant

Apr 21 2017

BRIEF-Apricus Biosciences files for offering of up to $6.0 mln of units

* Files for offering of up to $6.0 million of units, consisting of one share of common stock,warrant to purchase 0.75 of common share Source text for Eikon: Further company coverage:

Apr 17 2017

BRIEF-Apricus Biosciences files for offering of up to $6.9 mln shares - SEC filing

* Files for offering of up to $6.9 million of co's common stock - SEC filing Source text: (http://bit.ly/2nAN3OB) Further company coverage:

Mar 30 2017

BRIEF-Apricus Biosciences announces sale of ex-U.S. Vitaros assets, rights to Ferring Pharmaceuticals

* Apricus biosciences announces sale of ex-u.s. Vitaros assets and rights to ferring pharmaceuticals

Mar 08 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $32.67 -0.28
GlaxoSmithKline plc (GSK.L) 1,490.00 -16.00
Eli Lilly and Co (LLY.N) $77.07 -0.73
Abbott Laboratories (ABT.N) $48.74 -0.55

Earnings vs. Estimates